Literature DB >> 26203505

Management of pain following craniotomy.

Michael Puntis1, Anne Garner2.   

Abstract

Pain following craniotomy is common, however, achieving effective analgesia can be difficult. The assessment of pain postoperatively can be a challenge in patients who are obtunded (not fully alert) and the severity of pain has historically been underestimated. There are also concerns about side-effects from drugs, particularly with opioids, which may lead to reluctance to administer effective doses. Paracetamol is generally safe and, if given intravenously, provides rapid analgesia, although there are risks associated with overdose and care must be taken to ensure that the safe daily limit is not exceeded. Opioids are effective but side effects of pupillary constriction and respiratory depression may be problematic in the neurosurgical patient. The total use of systemic analgesia can be minimised with the use of regional techniques, such as local anaesthetic nerve blocks. A multimodal technique, using different agents, is most likely to be effective.

Entities:  

Keywords:  Analgesia; Craniotomy; Neurosurgery; Pain

Mesh:

Substances:

Year:  2015        PMID: 26203505     DOI: 10.12968/bjon.2015.24.14.740

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  3 in total

1.  Pain Quality Among Hospitalized Postcraniotomy Brain Tumor Patients.

Authors:  Rebecca E Foust Winton; Claire B Draucker; Diane Von Ah
Journal:  Clin Nurse Spec       Date:  2021 May-Jun 01       Impact factor: 1.143

2.  Pre-emptive scalp infiltration with ropivacaine plus methylprednisolone versus ropivacaine alone for relief of postoperative pain after craniotomy in children (RP/MP vs RP): a study protocol for a randomised controlled trial.

Authors:  Chunmei Zhao; Yitong Jia; Zipu Jia; Xiong Xiao; Fang Luo
Journal:  BMJ Open       Date:  2019-06-22       Impact factor: 2.692

Review 3.  Analgesia in the Neurosurgical Intensive Care Unit.

Authors:  Slavica Kvolik; Nenad Koruga; Sonja Skiljic
Journal:  Front Neurol       Date:  2022-01-25       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.